Elevation of serum thioredoxin in patients with gefitinib-induced interstitial lung disease

Internal Medicine

Volumn 46, Issue 23, 2007, Pages 1905-1909

  Sakuma, Keiichiro ^a,d   Nakamura, Hajime ^b   Nakamura, Takayuki ^b   Hoshino, Yuma ^b   Ueda, Shugo ^b   Ichikawa, Masataka ^a   Tabata, Chiharu ^a   Fujita, Sgiro ^a   Masago, Katsuhiro ^a   Yodoi, Junji ^c   Mishima, Michiaki ^a   Mio, Tadashi ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Gefitinib; Interstitial lung disease (ILD); Lung cancer; Oxidative stress; Thioredoxin (Trx)

Indexed keywords

GEFITINIB; THIOREDOXIN;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG CANCER; MALE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RISK FACTOR; SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; OXIDATIVE STRESS; QUINAZOLINES; THIOREDOXINS;

EID: 37549036277     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.0220     Document Type: Article

References (21)

1. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 91(Suppl 2): S18-23, 2004.
2. Nakamura H, Bai J, Nishinaka Y, et al. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev 24: 53-60, 2000.
3. Sumida Y, Nakashima T, Yoh T, et al. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J Hepatol 33: 616-622, 2000.
4. Abdiu A, Nakamura H, Sahaf B, Yodoi J, Holingren A, Rosen A. Thioredoxin blood level increases after severe bum injury. Antioxid Redox Signal 2: 707-716, 2000.
5. Nakamura H, De Rosa SC, Yodoi J, Holmgren A, Ghezzi P, Herzenberg LA. Chronic elevation of plasma thioredoxin: inhibition of chemotaxis and curtailment of life expectancy in AIDS. Proc Natl Acad Sci U S A 98: 2688-2693, 2001.
6. Jikimoto T, Nishikubo Y, Koshiba M, et al. Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Mol Immunol 38: 765-772, 2002.
7. Kishimoto C, Shioji K, Nakamura H, Nakayama Y, Yodoi J, Sasayama S. Serum thioredoxin (TRX) levels in patients with heart failure. Jpn Circ J 65: 491-494, 2001.
8. Yamada Y, Nakamura H, Adachi T, et al. Elevated serum levels of thioredoxin in patients with acute exacerbation of asthma. Immunol Lett 86: 199-205, 2003.
9. Callister ME, Burke-Gaffney AC, Quinlan GJ, et al. Extracellular thioredoxin levels are increased in patients with acute lung injury. Thorax 61: 521-527, 2006.
10. Kogaki H, Fujiwara Y, Yoshiki A, et al. Sensitive enzyme-linked immunosorbent assay for adult T-cell leukemia-derived factor and normal value measurement. J Clin Lab Anal 10: 257-261, 1996.
11. Nakamura H, De Rosa S, Roederer M, et al. Elevation of plasma thioredoxin levels in HIV-infected individuals. Int Inummol 8: 603-611, 1996.
12. Gon Y, Sasada T, Matsui M, et al. Expression of thioredoxin in bleomycin-injured airway epithelium: possible role of protection against bleomycin induced epithelial injury. Life Sci 68: 1877-1888, 2001.
13. Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 13: 491-498, 2001.
14. Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 29: 312-322, 2000.
15. Miyazaki K, Noda N, Okada S, et al. Elevated serum level of thioredoxin in patients with hepatocellular carcinoma. Biotherapy 11: 277-288, 1998.
16. Hoshino, T, Nakamura H, Okamoto M, et, al. Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury. Am J Respir Crit Care Med 168: 1075-1083, 2003.
17. Nakamura H, Tamura S, Watanabe I, Iwasaki T, Yodoi J. Enhanced resistancy of thioredoxin-transgenic mice against influenza virus-induced pneumonia. Immunol Lett 82: 165-170, 2002.
18. Hattori I, Takagi Y, Nakamura H, et al. Intravenous administration of thioredoxin decreases brain damage following transient focal cerebral ischemia in mice. Antioxid Redox Signal 6: 81-87, 2004.
19. Kaimul Ahsan M, Nakamura H, et al. Thioredoxin-1 suppresses lung injury and apoptosis induced by diesel exhaust particles (DEP) by scavenging reactive oxygen species and by inhibiting DEP-induced downregulation of Akt. Free Radic Biol Med 39: 1549-1559, 2005.
20. Kondo N, Ishii Y, Kwon YW, et al. Redox-sensing release of human thioredoxin from T lymphocytes with negative feedback loops. J Immunol 172: 442-448, 2004.
21. Nakamura H, Herzenberg LA, Bai J, et al. Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc Natl Acad Sci U S A 98: 15143-15148, 2001.